Humana Inc. (NYSE:HUM) Stake Lessened by Exencial Wealth Advisors LLC

Key Points

• Exencial Wealth Advisors LLC has reduced its stake in Humana Inc. by 12.7% during the first quarter, now holding 7,000 shares worth approximately $1.85 million.
• Despite the reduction by Exencial, other institutional investors such as Vanguard Group Inc. and Cary Street Partners have increased their holdings in Humana during the same period.
• Humana reported $6.27 EPS for the quarter, missing estimates, while also achieving a 9.6% year-over-year revenue increase to $32.39 billion.

Exencial Wealth Advisors LLC decreased its position in Humana Inc. (NYSE:HUM - Free Report) by 12.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,000 shares of the insurance provider's stock after selling 1,018 shares during the quarter. Exencial Wealth Advisors LLC's holdings in Humana were worth $1,852,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Humana by 8.9% in the 1st quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider's stock worth $3,697,222,000 after acquiring an additional 1,143,662 shares in the last quarter. Cary Street Partners Investment Advisory LLC grew its position in shares of Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock worth $31,000 after acquiring an additional 46 shares in the last quarter. Plan Group Financial LLC grew its position in shares of Humana by 66.5% in the 1st quarter. Plan Group Financial LLC now owns 1,695 shares of the insurance provider's stock worth $448,000 after acquiring an additional 677 shares in the last quarter. Blair William & Co. IL grew its position in shares of Humana by 11.6% in the 1st quarter. Blair William & Co. IL now owns 4,614 shares of the insurance provider's stock worth $1,221,000 after acquiring an additional 481 shares in the last quarter. Finally, Banco Santander S.A. acquired a new position in shares of Humana in the 1st quarter worth approximately $245,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Price Performance

HUM stock traded up $10.51 on Friday, hitting $266.65. 1,678,249 shares of the company's stock traded hands, compared to its average volume of 1,999,296. The stock has a market cap of $32.07 billion, a price-to-earnings ratio of 20.46, a P/E/G ratio of 1.51 and a beta of 0.44. Humana Inc. has a 1-year low of $206.87 and a 1-year high of $382.72. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. The stock has a fifty day moving average of $237.88 and a 200-day moving average of $254.38.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.32 by ($0.05). The business had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%. The company's quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter last year, the firm posted $6.96 EPS. On average, analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on HUM. Wells Fargo & Company set a $348.00 target price on Humana in a research report on Friday, July 18th. Oppenheimer increased their price target on Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research report on Thursday, May 1st. Cantor Fitzgerald reiterated a "neutral" rating and set a $290.00 price target on shares of Humana in a research report on Thursday, May 1st. Barclays set a $275.00 price target on Humana and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Finally, Bank of America dropped their price target on Humana from $320.00 to $260.00 and set a "neutral" rating on the stock in a research report on Tuesday, June 17th. Seventeen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $281.62.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.